B of A Securities Downgrades 17 Education & Technology to Underperform

B of A Securities analyst Lucy Yu downgrades 17 Education & Technology (NASDAQ:YQ) from Buy to Underperform.

byBenzinga Newsdesk

July 26, 2021

1 minute read

B of A Securities analyst Lucy Yu downgrades 17 Education & Technology (NASDAQ:YQ) from Buy to Underperform.

TCR2 Therapeutics Announces Topline Results From Phase 1 Portion Of gavo-cel Phase 1/2 Trial; Showed ‘Consistent tumor regression in 28 of 30 (93%) evaluable patients with disease control rate of 77%’

By Bill Haddad

Today, 10:48 AM

- Completed Phase 1 clinical trial establishes gavo-cel monotherapy as the first anti-mesothelin cell therapy to demonstrate tolerability and clinical benefit - Second RECIST partial response in ovarian cancer supports

TCRR

News

Velodyne Lidar’s Intelligent Infrastructure Solution Selected By HORIBA Institute For Mobility And Connectivity At UC Irvine Samueli School Of Engineering

By Bill Haddad

Today, 10:48 AM

Velodyne's Lidar-based Traffic Monitoring Solution to be Used at 25 Intersections as Part of $6 Million Road Network Project in Irvine, Calif. Velodyne Lidar, Inc. (NASDAQ:VLDR, VLDRW)))) today

VLDR

Panama Will Be A Pharmaceutical Hub For The Cannabis Industry – And This Event Will Be Fundamental To Its Development

By Nicolas Jose Rodriguez

Today, 10:48 AM

On September 1 and 2, 2022, LATAM CANN.BIZ will be held in Panama. More than 40 experts, executives, medical professionals and political actors meet to discover the opportunities for economic development, investment and scientific advances in the medical and industrial cannabis industry.

AVCNF

Tesla Q4 Sales Expected To Jump 43% On Robust December Deliveries: TrueCar

By Rachit Vats

Today, 10:48 AM

Tesla Inc’s (NASDAQ: TSLA) fourth-quarter sales in the U.S. are expected to jump 42.8% to 97,417 electric vehicles from a year ago and 28.8% over the previous quarter, the latest automotive industry forecast from TrueCar reflected on Wednesday.

B of A Securities Downgrades 17 Education & Technology to Underperform

Related Posts

TCR2 Therapeutics Announces Topline Results From Phase 1 Portion Of gavo-cel Phase 1/2 Trial; Showed ‘Consistent tumor regression in 28 of 30 (93%) evaluable patients with disease control rate of 77%’

Velodyne Lidar’s Intelligent Infrastructure Solution Selected By HORIBA Institute For Mobility And Connectivity At UC Irvine Samueli School Of Engineering

Panama Will Be A Pharmaceutical Hub For The Cannabis Industry – And This Event Will Be Fundamental To Its Development

Tesla Q4 Sales Expected To Jump 43% On Robust December Deliveries: TrueCar